Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 8/20 | 0.85 |
| ▸ | DRD2 | P14416 | 8/20 | 0.85 |
| ▸ | DRD3 | P35462 | 6/20 | 0.85 |
| ▸ | HTR1A | P08908 | 9/20 | 0.67 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.57 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8017069 | 0.93 | DRD2 (0.94) | ADRA1ADRD2DRD3HTR1A | |
| SCHEMBL8001303 | 0.89 | ADRA1A (0.69) | ADRA1ADRD2DRD3HTR1AADRA1D | |
| SCHEMBL9760272 | 0.88 | DRD2 (0.67) | ADRA1ADRD2DRD3HTR1AADRA1D | |
| SCHEMBL14672134 | 0.85 | ADRA1A (0.67) | ADRA1ADRD2DRD3HTR1AADRA1D | |
| SCHEMBL9055986 | 0.83 | HTR1A (0.65) | ADRA1ADRD2DRD3HTR1A | |
| SCHEMBL976063 | 0.83 | ADRA1A (0.73) | ADRA1ADRD2DRD3HTR1AADRA1D | |
| SCHEMBL4616926 | 0.81 | ADRA1A (0.62) | ADRA1ADRD2DRD3HTR1A | |
| SCHEMBL6934502 | 0.81 | DRD2 (0.66) | ADRA1ADRD2DRD3HTR1AADRA1D | |
| SCHEMBL6930794 | 0.81 | DRD2 (0.66) | ADRA1ADRD2DRD3HTR1AADRA1D | |
| SCHEMBL977564 | 0.81 | DRD2 (0.58) | ADRA1ADRD2DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7901667-B2 | Antibodies and adamantane-based compounds; antibodies | MALLINCKRODT INC. (US) | 2011-03-08 | — | — | US | claimed |
| EP-0512755-B1 | Piperazine derivatives | WYETH JOHN & BROTHER LTD (GB) | 1994-12-14 | — | — | EP | claimed |
| EP-0512755-A2 | Piperazine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1992-11-11 | — | — | EP | claimed |
| US-20230076320-A1 | NORFENFLURAMINE TO TREAT DRAVET SYNDROME | ZOGENIX INTERNATIONAL LIMITED (GB) | 2023-03-09 | — | — | US | disclosed |
| US-20220370381-A1 | COMPOSITIONS AND METHODS FOR TREATING SEIZURE DISORDERS | ZOGENIX INTERNATIONAL LIMITED (GB) | 2022-11-24 | — | — | US | disclosed |
| US-20150133663-A1 | NOVEL SYNTHESIS METHOD | GE HEALTHCARE LIMITED (GB) | 2015-05-14 | — | — | US | disclosed |
| US-20150133663-A1 | NOVEL SYNTHESIS METHOD | GE HEALTHCARE LIMITED (GB) | 2015-05-14 | — | — | US | disclosed |
| US-20150133663-A1 | NOVEL SYNTHESIS METHOD | GE HEALTHCARE LIMITED (GB) | 2015-05-14 | — | — | US | disclosed |
| EP-2758390-A1 | NOVEL SYNTHESIS METHOD | GE Healthcare UK Limited (GB) | 2014-07-30 | — | — | EP | disclosed |
| EP-2736898-A1 | 5HT1A ANTAGONIST USEFUL FOR IN VIVO IMAGING | GE Healthcare UK Limited (GB) | 2014-06-04 | — | — | EP | disclosed |
| US-20140140928-A1 | 5HT1A ANTAGONIST USEFUL FOR IN VIVO IMAGING | GE HEALTHCARE LIMITED (GB) | 2014-05-22 | — | — | US | disclosed |
| US-6127357-A | N-((phenyl, benzodioxinyl or N-heteroarylpiperazinyl)alkyl)-N-(N-heteroaryl)substituted carboxamides | JOHN WYETH & BROTHER, LTD. (GB) | 2000-10-03 | — | — | US | disclosed |
| US-5990114-A | ADMINISTERING 1,4-SUBSTITUTED PIPERAZINE DERIVATIVES OF GIVEN FORMULA TO TREAT NEUROMUSCULAR DYSFUNCTION OF THE LOWER URINARY TRACT; BOTH PRE- AND POST-SYNAPTIC ANTAGONISM; SUCH AS 1-(2-((2-PYRIDYLAMINO)ETHYL)-4-(4-INDOLYL)PIPERAZINE | RECORDATI, S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1999-11-23 | — | — | US | disclosed |
| EP-0906100-A1 | USE OF 5-HT 1A? RECEPTOR ANTAGONISTS FOR THE TREATMENT OF URINARY INCONTINENCE | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1999-04-07 | — | — | EP | disclosed |
| CN-1206589-A | Process for preparing medicine composition | WYETH JOHN & BROTHER LTD (GB) | 1999-02-03 | — | — | CN | disclosed |
| WO-1998023590-A1 | AROMATIC AMINES OF ARYLPIPERAZINES, THEIR PREPARATION AND APPLICATIONS AS MEDICINE | PIERRE FABRE MEDICAMENT (FR) | 1998-06-04 | — | — | WO | disclosed |
| WO-1997031637-A1 | USE OF 5-HT1A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF URINARY INCONTINENCE | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1997-09-04 | — | — | WO | disclosed |
| WO-1996001656-A1 | 5-HT1A LIGANDS | JOHN WYETH & BROTHER LIMITED (GB) | 1996-01-25 | — | — | WO | disclosed |
| EP-0512755-B1 | Piperazine derivatives | WYETH JOHN & BROTHER LTD (GB) | 1994-12-14 | — | — | EP | disclosed |
| EP-0512755-A2 | Piperazine derivatives | JOHN WYETH & BROTHER LIMITED (GB) | 1992-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230076320-A1 | NORFENFLURAMINE TO TREAT DRAVET SYNDROME | TPH2, HTR5A, TPH1 | ADRA1A 406/4885DRD2 218/4885DRD3 325/4885 |
| US-20150133663-A1 | NOVEL SYNTHESIS METHOD | HTR1A, HTR5A, TPH1 | ADRA1A 137/4885DRD2 36/4885DRD3 73/4885 |
| US-20140140928-A1 | 5HT1A ANTAGONIST USEFUL FOR IN VIVO IMAGING | HTR1A, HTR1E, HTR5A | ADRA1A 30/4885DRD2 80/4885DRD3 199/4885 |
| US-20220370381-A1 | COMPOSITIONS AND METHODS FOR TREATING SEIZURE DISORDERS | PSEN2, EPM2A, TPH2 | ADRA1A 784/4885DRD2 718/4885DRD3 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.